Irritable Bowel Syndrome with constipation (IBS-C) drugs industry is expanding at a CAGR of 6.3% from 2016 to 2022

The latest industry report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Constipation (IBS-C) industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with constipation (IBS-C) drugs industry was valued at USD 1,045 Mn in 2015, and is expected to reach USD 1,597.5 Mn by 2022, expanding at a CAGR of 6.3% from 2016 to 2022.

Industry Insights

The global IBS-C drugs industry is expected to progress at a CAGR of 6.3% during the forecast period. Europe is expected to be the largest regional industry for IBS-C drugs followed by North America and Asia Pacific. Gradual growth in physician and patient awareness corresponding to the perpetual growth in disease prevalence are the major growth contributors to the global IBS-C industry.

The global IBS-C drugs industry is expected to witness significant growth over the forecast period due to significant adoption of IBS drugs. The recent FDA approvals and currently successful clinical trials of IBS drugs will further surge the industry. Growing geriatric population and rise in healthcare expenditure are further creating huge scope for IBS-C drugs industry. IBS-C is much prevalent in developed world, where dietary habits, work conditions, and similar such factors contribute to higher risk of lifestyle-related gastrointestinal diseases.

Browse the full report Irritable Bowel Syndrome with Constipation (IBS-C) industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 report at

Among the regional industrys, Europe is expected to lead the global industry in terms of revenue share, expected to reach USD 639 Mn in 2022. Asia Pacific is the most emerging industry and is expected to contribute significantly during the forecast period and will undergo progress corresponding to the global trends. The major players in the global IBS-C industry include Sucampo AG, Activis, Cardinal Health, Catelent Pharma Solutions, Synergy Pharmaceuticals and others. Rapid commercialization, strong R&D activities, industry consolidation strategies brought up by these players will be the major progressive features of the industry. Introduction of highly targeted, orally administered peripherally acting mu-opioid receptor antagonist (PAMORA) therapies has also been a key industry event.

Drugs such as lubiprostone, methylnaltrexone ad others are widely used for treating IBS-C in North America., thus addressing symptoms such as stomach pain or cramps, bloating, and infrequent or difficult passage of stool. Adoption of these drugs is further higher among elderly population.

Though rare, some probable side effects of these drugs include nausea, further stomach pain, swelling on face, tightness in throat, and others. Majority of IBS-C drugs are widely accepted and the rise in FDA approvals to newer drugs are adding up to create further industry opportunities. As a result, several industry players are increasingly focusing on research and development activities to come with better and novel pharmaceutical solutions for treating IBS-C.

Sample Request

About Us:

Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

What we do

We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.

No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.


Name: Chris Smith

Designation: Global Sales Manager


Ph: 1-800-361-8290

Facebook Comments

Share this post